EUVIMEDEUVIMED entdecken
Crossref

Efficacy of Centanafadine in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder and High Executive Dysfunction: A Post Hoc Analysis of Two Phase 3 Trials

Wirksamkeit von Centanafadine bei Kindern und Jugendlichen mit Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung und hoher exekutiver Dysfunktion: Post-hoc-Analyse von zwei Phase-3-Studien

Timothy E Wilens iD, Ann C Childress, Greg W Mattingly, Judy van Stralen, Gregory S Parks, Zhen Zhang, Taisa Skubiak, Caroline L Ward

Journal of Child and Adolescent Psychopharmacology · 10.11.2026

DOI: 10.1177/10445463261503807 ↗

Auf einen Blick

Bei 435 Teilnehmenden mit hoher exekutiver Dysfunktion war Centanafadine über 6 Wochen mit besseren Verbesserungen der ADHS-Kernsymptome und mehrerer Begleitmerkmale als Placebo verbunden.

Fragestellung

Verbessert Centanafadine bei 6- bis 17-Jährigen mit ADHS und hoher exekutiver Dysfunktion die ADHS-Kernsymptome und Begleitmerkmale stärker als Placebo?

Methode

Post-hoc-Analyse gepoolter Daten aus 2 multizentrischen, randomisierten, doppelblinden, placebokontrollierten Phase-3-Studien in den USA und Kanada; Behandlung 6 Wochen.

Ergebnisse

Unter Centanafadine lagen die ADHD-RS-5-Werte in Woche 6 in der Hoch-Dysfunktion-Gruppe ähnlich wie in der Niedrig-Dysfunktion-Gruppe und niedriger als unter Placebo. Effektgrößen in Wochen 1–6: ADHD-RS-5 0,35–0,51; Inattention 0,33–0,56; Hyperactivity/Impulsivity 0,33–0,43; Executive Function 0,34–0,53; Learning Problems 0,36–0,52; Defiance/Aggression 0,19–0,36.

Einschränkungen

p-Werte wurden nicht für multiple Tests kontrolliert.

Schlussfolgerung der Autor:innen

Kinder, Jugendliche und junge Menschen mit hoher exekutiver Dysfunktion zeigten nach Centanafadine stärkere Verbesserungen von ADHS-Kernsymptomen und mehreren Begleitmerkmalen als unter Placebo.

Kernaussagen

  • 435 Teilnehmende mit hoher exekutiver Dysfunktion
  • Effektgrößen unter Centanafadine über Wochen 1–6
  • Keine neuen Sicherheitsbedenken identifiziert

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Child and Adolescent Psychopharmacology, online erschienen am 10.11.2026. Verfasst von Timothy E Wilens und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Child and Adolescent Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. Die Arbeit nennt 30 Literaturangaben. Gefördert von: Otsuka Pharmaceutical Development and Commercialization.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

High levels of executive dysfunction associated with attention-deficit/hyperactivity disorder (ADHD) have been linked to poorer response to pharmacotherapy. This post hoc analysis assessed the efficacy of centanafadine in the treatment of ADHD core symptoms and associated features in a subgroup of children and adolescents with high executive dysfunction.

Methods

Data were pooled from two phase 3, multicenter, randomized, double-blind, placebo-controlled trials conducted in the United States and Canada in children (6–12 years) and adolescents (13–17 years) with a primary diagnosis of ADHD who received centanafadine or placebo for 6 weeks. High levels of executive dysfunction were defined using a baseline Conners 3–Parent Short Executive Function T-score of ≥70. Efficacy outcomes assessed change from baseline in ADHD core symptoms and associated features. The p values were not controlled for multiplicity. Effect sizes were calculated using Cohen’s d method based on mixed models for repeated measures estimates and are shown for outcomes that separated from placebo.

Results

Among 435 participants with high executive dysfunction, baseline ADHD Rating Scale-5 (ADHD-RS-5) total scores and Conners 3–Parent Short T-scores for Inattention, Hyperactivity/Impulsivity, Defiance/Aggression, and Learning Problems were all greater than in the low dysfunction subgroup. By Week 6, ADHD-RS-5 scores in the centanafadine-treated high dysfunction subgroup were similar to those in the centanafadine-treated low dysfunction subgroup and were lower than in the placebo-treated subgroups. Over Weeks 1–6, effect sizes in the high executive dysfunction subgroup ranged from 0.35 to 0.51 for ADHD-RS-5, 0.33 to 0.56 for Conners 3–Parent Short Inattention, 0.33 to 0.43 for Hyperactivity/Impulsivity, 0.34 to 0.53 for Executive Function, 0.36 to 0.52 for Learning Problems, and 0.19 to 0.36 for Defiance/Aggression. No new safety concerns were identified.

Conclusions

Individuals aged 6–17 years with high levels of executive dysfunction achieved greater improvements in ADHD core symptoms and in several associated features, including executive dysfunction and emotional dysregulation, following centanafadine treatment when compared with placebo.

Schlagwörter

Stichwörter der Autor:innen

adolescentsattention-deficit/hyperactivity disordercentanafadinechildrenexecutive dysfunctionexecutive function

Autor:innen und Institutionen

  • Division of Child and Adolescent Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Center for Psychiatry and Behavioral Medicine, Inc., Las Vegas, Nevada, USA.
  • Midwest Research Group, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Center for Pediatric Excellence, Ottawa, Ontario, Canada.
  • Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, New Jersey, USA.

ORCID-Profile: Timothy E Wilens

Förderung

  • Otsuka Pharmaceutical Development and Commercialization

Zitieren

APA

Wilens, T. E., Childress, A. C., Mattingly, G. W., van Stralen, J., Parks, G. S., Zhang, Z., Skubiak, T., & Ward, C. L. (2026). Efficacy of Centanafadine in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder and High Executive Dysfunction: A Post Hoc Analysis of Two Phase 3 Trials. Journal of Child and Adolescent Psychopharmacology. https://doi.org/10.1177/10445463261503807

Vancouver

Wilens TE, Childress AC, Mattingly GW, van Stralen J, Parks GS, Zhang Z, et al. Efficacy of Centanafadine in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder and High Executive Dysfunction: A Post Hoc Analysis of Two Phase 3 Trials. Journal of Child and Adolescent Psychopharmacology. 2026. doi:10.1177/10445463261503807

BibTeX
@article{Wilens2026,
  author = {Wilens, Timothy E and Childress, Ann C and Mattingly, Greg W and van Stralen, Judy and Parks, Gregory S and Zhang, Zhen and Skubiak, Taisa and Ward, Caroline L},
  title = {Efficacy of Centanafadine in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder and High Executive Dysfunction: A Post Hoc Analysis of Two Phase 3 Trials},
  journal = {Journal of Child and Adolescent Psychopharmacology},
  year = {2026},
  doi = {10.1177/10445463261503807}
}
Kostenlos starten →